🔎 Trials Near Me

Gara Jalqabaatti › Luukemiya Limfoositiikii Keessummaa › New York › New York City

Qorannoo klinikaalii Luukemiya Limfoositiikii Keessummaa New York City, NY keessatti

Qorannoo 18 Luukemiya Limfoositiikii Keessummaa f New York City fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Namoota walitti qabaa jiraSadarkaa 1/2
  • Columbia University Medical Center, New York
  • Weill Cornell Medical College Newyork Presbyterian Hospital, New York
  • Memorial Sloan Kettering Cancer Center Mskcc, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT05006716

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Umuriin 40 hanga 75 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT05334069

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Namoota walitti qabaa jiraSadarkaa 3
  • Memorial Sloan Kettering Cancer Center, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT04269902

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Namoota walitti qabaa jiraSadarkaa 1/2
  • Research Site, New York
  • Research Site, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT06542250

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Namoota walitti qabaa jiraSadarkaa 3
  • Columbia University Medical Center, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT07277231

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Namoota walitti qabaa jiraSadarkaa 3
  • Columbia University Medical Center, New York
  • Weill Cornell Medical College Newyork Presbyterian Hospital, New York
  • Memorial Sloan Kettering Cancer Center Mskcc, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT06973187

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Namoota walitti qabaa jiraSadarkaa 4
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07218341

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Namoota walitti qabaa jiraSadarkaa 3
  • David H. Koch Center for Cancer Care, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT07648264

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Namoota walitti qabaa jiraSadarkaa 1/2
  • Research Site, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 08-Ful-2026 · NCT06564038

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Namoota walitti qabaa jiraSadarkaa 1
  • Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 08-Ful-2026 · NCT03666000

Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

Namoota walitti qabaa jiraSadarkaa 2
  • Memorial Sloan Kettering Cancer Center, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Hag-2026 · NCT06849713

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Namoota walitti qabaa jiraSadarkaa 3
  • Icahn School of Medicine at Mount Sinai /ID# 266328, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Elb-2026 · NCT06428019

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

Namoota walitti qabaa jiraSadarkaa 2
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Bit-2026 · NCT07218510

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Namoota walitti qabaa jiraSadarkaa 4
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Bit-2026 · NCT06876649

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Namoota walitti qabaa jiraSadarkaa 4
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Bit-2026 · NCT06876662

Study of SGR-1505 in Mature B-Cell Neoplasms

Namoota walitti qabaa jiraSadarkaa 1
  • Weill Cornell, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Gur-2026 · NCT05544019

Qorannoo Luukemiya Limfoositiikii Keessummaa magaalota biroo keessatti

Qorannoo biroo New York City keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.